The acquisition of Bigfoot Biomedical, a company that develops smart insulin management systems, could potentially enhance Abbott's product portfolio in the diabetes management market. This could lead to increased market share and revenues in the long term. However, the financial impact of the deal is uncertain as the terms were not disclosed.